Comparative Pharmacology
Head-to-head clinical analysis: MAOLATE versus NORGESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAOLATE versus NORGESIC.
MAOLATE vs NORGESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
NORGESIC is a combination of orphenadrine citrate, aspirin, and caffeine. Orphenadrine is a centrally acting muscle relaxant with anticholinergic properties; its exact mechanism is not fully understood, but it may act via central atropine-like effects and inhibition of reuptake of norepinephrine and serotonin. Aspirin inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, leading to analgesic, antipyretic, and anti-inflammatory effects. Caffeine is a central nervous system stimulant that may enhance analgesia via adenosine receptor antagonism.
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
1-2 tablets orally 2-4 times daily. Each tablet contains orphenadrine citrate 100 mg and acetaminophen 325 mg.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for CrCl <30 mL/min)
Terminal elimination half-life is 2–4 hours; clinical multiple dosing may require 4–6 hour intervals
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Primarily renal (70% as unchanged drug and metabolites; 10% as unchanged) and biliary (30%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant